TRENTON – A Kenilworth, New Jersey-based lab and its owner/CEO agreed to pay $2.93 million to NJ Medicaid, the Office of the State Comptroller (OSC) announced today.
Eric Leykin, CEO/owner of RDx Bioscience, agreed to pay $2.93 million to New Jersey Medicaid. Leykin and RDx also agreed to pay the United States $10.32 million. In the settlement with OSC, Leykin acknowledged routinely overcharging Medicaid for lab tests, conducting unnecessary lab tests, and lacking documentation for claims, including missing signatures. All of this conduct violates Medicaid regulations.
“Overcharging Medicaid and conducting unnecessary tests is wasteful, improper, and harmful,” said Kevin Walsh, Acting State Comptroller. “It drains resources from people in need.”